Sign in or create an account to add this stock to your watchlist.
About Durata Therapeutics (NASDAQ:DRTX)
Durata Therapeutics, Inc. is a pharmaceutical company focused on the development and commercialization of therapeutics for patients with infectious diseases and acute illnesses. The Company enroll and dose patients in two global Phase III clinical trials with its product candidate, dalbavancin, for the treatment of patients with acute bacterial skin and skin structure infections (abSSSI). Dalbavancin is an intravenous antibiotic product candidate designed for once-weekly dosing. In addition to abSSSI, the Company focuses on the development of dalbavancin for additional indications, including osteomyelitis, diabetic foot infection and pneumonia. As of December 31, 2011, Dalbavancin had already completed three Phase III clinical trials, in which more than 1,000 patients in total received dalbavancin.
Industry, Sector and Symbol
Industry N/A
Sub-IndustryBiotechnology
SectorN/A
SymbolNASDAQ:DRTX
CUSIP26658A10
WebN/A
Phone+1-312-2197000
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
EmployeesN/A
Outstanding SharesN/A
Durata Therapeutics (NASDAQ:DRTX) Frequently Asked Questions
What is Durata Therapeutics' stock symbol?
Durata Therapeutics trades on the NASDAQ under the ticker symbol "DRTX."
Has Durata Therapeutics been receiving favorable news coverage?
Media coverage about DRTX stock has been trending somewhat positive on Sunday, Accern Sentiment Analysis reports. Accern identifies negative and positive press coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Durata Therapeutics earned a news impact score of 0.01 on Accern's scale. They also gave news headlines about the biotechnology company an impact score of 45.81 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the near term.
How do I buy shares of Durata Therapeutics?
Shares of DRTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How can I contact Durata Therapeutics?
Durata Therapeutics' mailing address is 200 S Wacker Dr Ste 2550, CHICAGO, IL 60606-5811, United States. The biotechnology company can be reached via phone at +1-312-2197000.
MarketBeat Community Rating for Durata Therapeutics (DRTX)
MarketBeat's community ratings are surveys of what our community members think about Durata Therapeutics and other stocks. Vote "Outperform" if you believe DRTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DRTX will underperform the S&P 500 over the long term. You may vote once every thirty days.
Durata Therapeutics (NASDAQ:DRTX) Analyst Ratings History
| Date | Brokerage | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
(Data available from 5/20/2016 forward)
Durata Therapeutics (NASDAQ:DRTX) Earnings History and Estimates Chart
Durata Therapeutics (NASDAQ DRTX) Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 8/7/2014 | Q2 | ($0.73) | ($0.61) | | | View | N/A |  |
| 5/8/2014 | Q114 | ($0.61) | ($0.65) | | | View | N/A | |
| 3/14/2014 | Q413 | ($0.76) | ($0.59) | | | View | N/A | |
| 11/6/2013 | Q3 2013 | ($0.60) | ($0.45) | | | View | N/A | |
| 8/7/2013 | Q2 2013 | ($0.52) | ($0.75) | | | View | N/A | |
| 5/9/2013 | 1Q13 | ($0.66) | ($0.86) | | | View | N/A | |
| 11/9/2012 | Q312 | ($1.00) | ($1.47) | | | View | N/A | |
| 9/4/2012 | Q2 2012 | ($1.08) | ($256.56) | | | View | N/A | |
(Earnings results data provided by Zacks Investment Research)
Durata Therapeutics (NASDAQ:DRTX) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Durata Therapeutics (NASDAQ DRTX) Insider Trading and Institutional Ownership History
Durata Therapeutics (NASDAQ DRTX) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 8/12/2014 | John Patrick Shannon Jr | Insider | Buy | 3,000 | $13.72 | $41,160.00 | | |
| 6/12/2014 | Paul R Edick | CEO | Buy | 3,000 | $15.23 | $45,690.00 | | |
| 5/12/2014 | Schutter Richard De | Director | Buy | 15,000 | $15.57 | $233,550.00 | 15,000 | |
| 3/21/2014 | Aisling Capital Iii Lp | major shareholder | Sell | 100,649 | $15.74 | $1,584,215.26 | | |
| 12/3/2013 | Lisa Giles | Director | Buy | 1,000 | $10.95 | $10,950.00 | 1,000 | |
| 5/20/2013 | Paul R Edick | CEO | Buy | 3,000 | $7.09 | $21,270.00 | | |
| 8/14/2012 | Paul R Edick | CEO | Buy | 5,000 | $8.65 | $43,250.00 | | |
(Data available from 1/1/2013 forward)
Durata Therapeutics (NASDAQ DRTX) News Headlines
| Source: |
|
Durata Therapeutics (NASDAQ:DRTX) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Durata Therapeutics (NASDAQ:DRTX) Income Statement, Balance Sheet and Cash Flow Statement
Durata Therapeutics (NASDAQ DRTX) Stock Chart for Sunday, May, 20, 2018
Loading chart…
